TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07850453: Randomized, Double-blind, Phase II Trial of Vortosiran to Evaluate Safety, Tolerability, and Pharmacodynamic Efficacy in Participants With Prior Venous Thromboembolism After Completion of Initial Anticoagulant Therapy (C

Sponsor: Ribocure Pharmaceuticals AB · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 150 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$6,652,800

Rescue Site Savings

+$4,389,000

Unlock Full NCT07850453 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07850453 Rescue Dossier →